Biomarker Testing for Radiation Heart Disease in Lung Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
The study will measure serum Pro-N-Cadherin and NT-proBNP (pro B-type natriuretic peptide) levels in adults with non-small cell lung cancer receiving hypofractionated radiation therapy and evaluate whether these biomarkers correlate with radiation dose to the heart, cardiac dysfunction, and adverse cardiac events. Participants will undergo blood collection and echocardiography over a two-year follow-up period.
Who Is on the Research Team?
Christopher Kelsey, MD
Principal Investigator
Duke Health
Chang-Lung Lee, PhD
Principal Investigator
Duke Health
Are You a Good Fit for This Trial?
This trial is for adults with non-small cell lung cancer who are receiving a specific type of radiation therapy. Participants must be able to provide blood samples and undergo heart ultrasound exams over two years.Inclusion Criteria
Exclusion Criteria
What Are the Treatments Tested in This Trial?
Trial Overview
Researchers are studying whether certain blood markers (Pro-N-Cadherin and NT-proBNP) can predict heart problems caused by radiation in lung cancer patients. Blood tests and heart ultrasounds will be done during the study.
How Is the Trial Designed?
1
Treatment groups
Experimental Treatment
Adults with non-small cell lung cancer receiving hypofractionated radiation therapy will undergo biomarker testing and echocardiographic assessments.
Find a Clinic Near You
Who Is Running the Clinical Trial?
Duke University
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Collaborator
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.